Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
Descriptor ID |
D056572
|
MeSH Number(s) |
D27.505.519.389.360
|
Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2001 | 2 | 2 | 4 |
2002 | 1 | 2 | 3 |
2003 | 5 | 4 | 9 |
2004 | 8 | 1 | 9 |
2005 | 6 | 8 | 14 |
2006 | 7 | 7 | 14 |
2007 | 12 | 5 | 17 |
2008 | 8 | 6 | 14 |
2009 | 11 | 6 | 17 |
2010 | 12 | 14 | 26 |
2011 | 14 | 5 | 19 |
2012 | 8 | 14 | 22 |
2013 | 12 | 8 | 20 |
2014 | 9 | 6 | 15 |
2015 | 9 | 10 | 19 |
2016 | 7 | 8 | 15 |
2017 | 6 | 6 | 12 |
2018 | 4 | 1 | 5 |
2019 | 3 | 5 | 8 |
2020 | 5 | 4 | 9 |
2021 | 2 | 4 | 6 |
2022 | 0 | 5 | 5 |
2023 | 0 | 1 | 1 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Critical Role of histone deacetylase 3 in the regulation of kidney inflammation and fibrosis. Kidney Int. 2024 Apr; 105(4):775-790.
-
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
-
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
-
HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget. 2022 10 14; 13:1122-1135.
-
HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling. J Neurosci. 2022 10 19; 42(42):7862-7874.
-
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. J Zhejiang Univ Sci B. 2022 Aug 15; 23(8):666-681.
-
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. Curr Hematol Malig Rep. 2022 10; 17(5):155-169.
-
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro Oncol. 2022 04 01; 24(4):655-664.
-
An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway. Brain Behav Immun. 2022 02; 100:287-296.